These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 35659629)

  • 1. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy.
    Zamboglou C; Strouthos I; Sahlmann J; Farolfi A; Serani F; Medici F; Cavallini L; Morganti AG; Trapp C; Koerber SA; Peeken JC; Vogel MME; Schiller K; Combs SE; Eiber M; Vrachimis A; Ferentinos K; Spohn SKB; Kirste S; Gratzke C; Ruf J; Grosu AL; Ceci F; Fendler WP; Miksch J; Kroeze S; Guckenberger M; Lanzafame H; Fanti S; Hruby G; Wiegel T; Emmett L; Schmidt-Hegemann NS; Henkenberens C
    Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1015-1024. PubMed ID: 35659629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
    Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2529-2536. PubMed ID: 36905411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
    Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):558-567. PubMed ID: 37736808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study.
    Janbain A; Farolfi A; Guenegou-Arnoux A; Romengas L; Scharl S; Fanti S; Serani F; Peeken JC; Katsahian S; Strouthos I; Ferentinos K; Koerber SA; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SK; Grosu AL; Ceci F; Henkenberens C; Kroeze SG; Guckenberger M; Belka C; Bartenstein P; Hruby G; Emmett L; Omerieh AA; Schmidt-Hegemann NS; Mose L; Aebersold DM; Zamboglou C; Wiegel T; Shelan M
    JMIR Cancer; 2024 Sep; 10():e60323. PubMed ID: 39303279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Harsini S; Martineau P; Plaha S; Saprunoff H; Chen C; Bishop J; Tyldesley S; Wilson D; Bénard F
    Cancer Imaging; 2024 Aug; 24(1):117. PubMed ID: 39210431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Outcomes from
    Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
    J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
    Armstrong WR; Kishan AU; Booker KM; Grogan TR; Elashoff D; Lam EC; Clark KJ; Steinberg ML; Fendler WP; Hope TA; Nickols NG; Czernin J; Calais J
    Eur Urol; 2024 Jul; 86(1):52-60. PubMed ID: 38290964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis.
    Spohn SKB; Farolfi A; Schandeler S; Vogel MME; Ruf J; Mix M; Kirste S; Ceci F; Fanti S; Lanzafame H; Serani F; Gratzke C; Sigle A; Combs SE; Bernhardt D; Gschwend JE; Buchner JA; Trapp C; Belka C; Bartenstein P; Unterrainer L; Unterrainer M; Eiber M; Nekolla SG; Schiller K; Grosu AL; Schmidt-Hegemann NS; Zamboglou C; Peeken JC
    Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):218-227. PubMed ID: 35984452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
    BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure Patterns by PSMA PET for Recurrent Prostate Cancer after Prostatectomy and Salvage Radiation.
    Imber BS; O'Dwyer E; Lobaugh S; McBride SM; Hopkins M; Kollmeier M; Gorovets D; Brennan V; Pike LRG; Gewanter R; Mychalczak B; Zhang Z; Schöder H; Zelefsky MJ
    Urology; 2022 Dec; 170():146-153. PubMed ID: 36115426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy.
    Wenzel M; Hussein R; Maurer T; Karakiewicz PI; Tilki D; Graefen M; Würnschimmel C
    Urol Oncol; 2022 Jan; 40(1):7.e1-7.e8. PubMed ID: 34340868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.
    Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Lanzafame H; Giuseppe Morganti A; Trapp C; Koerber SA; Debus J; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Ruf J; Grosu AL; Ceci F; Fendler WP; Bartenstein P; Kroeze SGC; Guckenberger M; Krafcsik M; Klopscheck C; Fanti S; Hruby G; Emmett L; Belka C; Stief C; Schmidt-Hegemann NS; Henkenberens C; Mayer B; Miksch J; Shelan M; Aebersold DM; Thamm R; Wiegel T
    Radiother Oncol; 2023 Jul; 184():109678. PubMed ID: 37146766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-Year Freedom from Progression After
    Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P
    J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
    [No Abstract]   [Full Text] [Related]  

  • 15. Patterns of relapse as determined by
    Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
    Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
    Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L;
    BJU Int; 2024 Feb; 133 Suppl 3():39-47. PubMed ID: 37604702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer.
    Zamboglou C; Peeken JC; Janbain A; Katsahian S; Strouthos I; Ferentinos K; Farolfi A; Koerber SA; Debus J; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SKB; Shelan M; Aebersold DM; Grosu AL; Ceci F; Henkenberens C; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Bartenstein P; Hruby G; Scharl S; Wiegel T; Emmett L; Arnoux A; Schmidt-Hegemann NS
    JAMA Netw Open; 2023 May; 6(5):e2314748. PubMed ID: 37219907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
    Schmidt-Hegemann NS; Fendler WP; Ilhan H; Herlemann A; Buchner A; Stief C; Eze C; Rogowski P; Li M; Bartenstein P; Ganswindt U; Belka C
    Radiat Oncol; 2018 Mar; 13(1):37. PubMed ID: 29499730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.